The Gut Microbiota and Traditional Chinese Medicine: A New Clinical Frontier on Cancer.

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current drug targets Pub Date : 2021-01-01 DOI:10.2174/1389450122666210412141304

Yan-Zhen Chen, Meng-Yun Yuan, Ya Ling Chen, Xingxing Zhang, Xin-Tian Xu, Shen-Lin Liu, Xi Zou, Jia-Lei Tao, Yong-Hu Qiang, Jian Wu, Qing-Min Sun

{"title":"The Gut Microbiota and Traditional Chinese Medicine: A New Clinical Frontier on Cancer.","authors":"Yan-Zhen Chen, Meng-Yun Yuan, Ya Ling Chen, Xingxing Zhang, Xin-Tian Xu, Shen-Lin Liu, Xi Zou, Jia-Lei Tao, Yong-Hu Qiang, Jian Wu, Qing-Min Sun","doi":"10.2174/1389450122666210412141304","DOIUrl":null,"url":null,"abstract":"<p><p>Gut microbiota is a complex microecosystem, which is called the second genome of the human body. Herbal medicine can balance tumor-suppressing bacteria and tumor-promoting bacteria and exert its anti-cancer effect by regulating gut microbiota. Traditional Chinese medicine (TCM) has a history of thousands of years in prevention and treatment of diseases in China. In recent decades, TCM has been shown to have an obvious advantage in prolonging the survival time and improving the living quality of patients with cancer. Notably, gut microbiota has become a new pathway to understanding TCM. In this review, we will focus on gut microbiota and tumor progression, especially the diversity, functionality and metabolites of gut microbiota affected by TCM in various cancer. We will also discuss the potential mechanism of gut microbiota for exploring TCM in anti-cancer effect. This article aims to comprehensively review the anti-cancer research of TCM by regulating gut microbiota, and address future perspectives and challenges of gut microbiota in TCM intervention for cancer.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":"22 11","pages":"1222-1231"},"PeriodicalIF":3.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1389450122666210412141304","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 11

Abstract

Gut microbiota is a complex microecosystem, which is called the second genome of the human body. Herbal medicine can balance tumor-suppressing bacteria and tumor-promoting bacteria and exert its anti-cancer effect by regulating gut microbiota. Traditional Chinese medicine (TCM) has a history of thousands of years in prevention and treatment of diseases in China. In recent decades, TCM has been shown to have an obvious advantage in prolonging the survival time and improving the living quality of patients with cancer. Notably, gut microbiota has become a new pathway to understanding TCM. In this review, we will focus on gut microbiota and tumor progression, especially the diversity, functionality and metabolites of gut microbiota affected by TCM in various cancer. We will also discuss the potential mechanism of gut microbiota for exploring TCM in anti-cancer effect. This article aims to comprehensively review the anti-cancer research of TCM by regulating gut microbiota, and address future perspectives and challenges of gut microbiota in TCM intervention for cancer.

查看原文本刊更多论文

肠道菌群与中医:癌症的新临床前沿。

肠道菌群是一个复杂的微生态系统，被称为人体的第二基因组。草药可以平衡抑瘤菌和促瘤菌，通过调节肠道菌群发挥抗癌作用。在中国，中医在预防和治疗疾病方面有着几千年的历史。近几十年来，中医药在延长癌症患者生存时间和提高患者生活质量方面已显示出明显的优势。值得注意的是，肠道菌群已成为了解中医的新途径。在这篇综述中，我们将重点关注肠道微生物群和肿瘤进展，特别是中药对各种癌症肠道微生物群的多样性、功能和代谢物的影响。我们还将讨论肠道菌群的潜在机制，以探索中药的抗癌作用。本文旨在全面综述中医药通过调节肠道菌群的抗癌研究，并探讨肠道菌群在中医药干预癌症中的应用前景和挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug targets 医学-药学

CiteScore

6.20

自引率

0.00%

发文量

127

审稿时长

3-8 weeks

期刊介绍： Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.